Amneal wins FDA approval for two denosumab biosimilars, expanding lower-cost treatment options for bone loss and cancer patients.

Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related ...

Denosumab (Prolia) is a leading treatment for osteoporosis, but the rapid bone loss that can occur after discontinuing the RANK ligand inhibitor can be challenging to navigate. "I don't think we have ...

Please provide your email address to receive an email when new articles are posted on . “Although we observed an increasing number of osteonecrosis of the jaw cases in our daily practice during the ...

Please provide your email address to receive an email when new articles are posted on . Denosumab is associated with a greater increase in lumbar spine bone mineral density at 12 months compared with ...

Dialysis patients on denosumab (Prolia, Xgeva) had a lower risk for fracture but higher risk for a certain heart event, suggested an observational trial weighted to emulate a clinical trial. Among ...

FDA approval based on robust clinical studies and totality of evidence, which show no clinically meaningful differences from reference medicines Keren Haruvi, President Sandoz North America, said: ...

HOUSTON — High-risk osteoporosis patients who are transitioned to the antiresorptive drug denosumab (Prolia, Amgen) following a previous regimen that includes teriparatide (Forteo, Eli Lilly) show the ...

Results of a large phase III randomized controlled trial—recently published online in the Lancet—have shown that denosumab can delay the onset of bone metastasis in patients with castration-resistant ...